The startup develops an AI-based medical diagnostic software that automates histological analysis by digitizing tissue slides and creating a comprehensive image database. This technology enhances cancer detection accuracy and increases the number of diagnoses while ensuring consistent reliability in identifying tissue damage.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pathologists face increasing workloads and complexity in cancer diagnosis, leading to potential for errors and delays in treatment decisions. Manual histological analysis is time-consuming and subjective, resulting in variability and limiting the ability to precisely quantify biomarkers.
Solution
Primaa offers an AI-powered platform that automates cancer diagnosis through digitized tissue slide analysis. The platform leverages image analysis and deep learning to improve the detection of major cancer biomarkers, enabling more accurate and personalized treatment decisions. By automating the analysis process, Primaa aims to reduce the workload on pathologists, accelerate case reviews, and enhance the precision and confidence in diagnosis. The platform's intelligent triage and case prioritization features further streamline the workflow, leading to faster diagnoses and improved patient outcomes.
Target Audience
The primary target audience includes pathologists and medical professionals involved in cancer diagnosis, as well as hospitals and diagnostic laboratories seeking to improve efficiency and accuracy.
Features
- AI-powered detection of cancer biomarkers from digitized tissue slides
- Image analysis and deep learning algorithms for accurate diagnosis
- Intelligent triage and case prioritization for streamlined workflow
- Automated TILs scoring tool
- Automatic detection and measurement of malignant lesions in WSIs for Squamous-Cell Carcinoma, Melanoma, and Basal-Cell Carcinoma
- End-to-End Pipeline for automatic IHC grading in Breast Cancer
- Solutions for breast cancer (Cleo Breast) and skin cancer (Cleo Skin)